马来酸曲美布汀治疗缓解期溃疡性结肠炎肠易激综合征样症状的疗效观察  

Efficacy of Trimebutine Maleate for IBS-like symptoms in ulcerative colitis patients at the stage of remission

作　　者：杨雪[1] 康长明[1] 李汉华[1] 邱春华[1] YANG Xue;KANG Chang-ming;LI Han-hua;QIU Chun-hua(Department of Gastroenterology,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,Chengdu 610072,China)

机构地区：[1]四川省医学科学院.四川省人民医院消化内科,四川成都610072

出　　处：《实用医院临床杂志》2018年第1期23-26,共4页Practical Journal of Clinical Medicine

基　　金：四川省卫生和计划生育委员会科研资助项目(编号:16PJ420)

摘　　要：目的探讨马来酸曲美布汀治疗缓解期溃疡性结肠炎(ulcerative colitis,UC)肠易激综合征样症状(IBS-like symptoms)的疗效及安全性。方法纳入具有IBS样症状的缓解期UC患者25例,在维持期治疗基础上接受马来酸曲美布汀治疗。观察治疗前、治疗14d及停药28d患者IBS样症状积分、焦虑评分(SAS)、抑郁评分(SDS)和生活质量评分(SF-36)变化。结果治疗后患者的IBS样症状缓解,焦虑抑郁状态改善,生活质量提高。治疗前后各项评分差异均有统计学意义(P<0.05)。停药28d患者的IBS样症状积分及SAS评分仍低于治疗前(P<0.05)。随访中仅2例出现轻微不良反应。结论马来酸曲美布汀能安全有效地治疗缓解期UC患者的IBS样症状。Objective To observe the clinical efficacy and safety of Trimebutine Maleate in the treatment of IBS-like symptoms in ulcerative colitis(UC)patients at remission stage.Methods A total of 25 UC patients at remission stage with IBS-like symptoms received treatment of Trimebutine Maleate.The scores of IBS-like symptom,SAS,SDS and SF-36 were evaluated at baseline,after 14 days supplementation and after 28 days withdrawal.Results After treatment,IBS-like symptoms were alleviated,anxiety and depression were relieved,and qualities of life were improved.There were significant differences in all the scores before and after treatment(P<0.05).After 28 days withdrawal,the scores of IBS-like symptom and SAS were still lower than baseline(P<0.05).Only 2 cases had slight adverse reactions during the follow-up.Conclusion Trimebutine Maleate is effective and safe for IBS-like symptoms in UC patients at remission stage.

关 键 词：马来酸曲美布汀 溃疡性结肠炎 缓解期 肠易激综合征样症状 

分 类 号：R574.62[医药卫生—消化系统]